Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01406223 · ClinicalTrials.gov registry record · Phase 3
Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
NCT01406223 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 282 participants.
The verdict
NCT01406223, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
Study Summary
The purpose of this study is to look at brain function in order to understand how different treatments work to help people quit smoking. In this study, the investigators will look at the effects of nicotine patches, Chantix alone or Chantix paired with Zyban.
Interventions
- DRUG Varenicline
- DRUG Bupropion
- DRUG Nicotine patches
- OTHER Placebo varenicline
- OTHER Placebo bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01406223
The ClinicalTrials.gov registry entry for NCT01406223 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Varenicline is the first listed.
NCT01406223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01406223 about?
NCT01406223 is a clinical study titled "Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation". The purpose of this study is to look at brain function in order to understand how different treatments work to help people quit smoking. In this study, the investigators will look at the effects of nicotine patches, Chantix alone or Chantix paired with Zyban.
What is the current status of trial NCT01406223?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2011-07. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01406223?
The interventions under investigation include: Varenicline (DRUG), Bupropion (DRUG), Nicotine patches (DRUG), Placebo varenicline (OTHER), Placebo bupropion (OTHER).
Who is sponsoring clinical trial NCT01406223?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.